The NY Times reports that a federal judge on Monday struck down patents on two genes linked to breast and ovarian cancer. The decision, if upheld, could throw into doubt the patents covering thousands of human genes and reshape the law of intellectual property.
U.S. Judge Invalidates Human Gene Patent
March 30, 2010
Share this post
2 Comments

Law Bytes
Episode 242: Sukesh Kamra on Law Firm Adoption of Artificial Intelligence and Innovative Technologies
byMichael Geist

July 28, 2025
Michael Geist
July 21, 2025
Michael Geist
June 30, 2025
Michael Geist
Search Results placeholder
Recent Posts
Grocery Shopping While Jewish
Privacy Lost: How the Government Deleted Bill C-11’s Key Privacy Principle Just Two Months After Passing it Into Law
Out of Nowhere: TIFF Undermines Artistic Freedom of Expression With Forced Name Change of October 7th Documentary
TIFF Removes October 7th Documentary Film From Schedule Citing Implausible Copyright Clearance Concerns From Hamas Terror Footage
Carney’s Digital Recalibration: How the Government is Trending Away from Justin Trudeau’s Digital Policy
“Myriad Genetics, the company that holds the patents with the University of Utah Research Foundation, asked the court to dismiss the case, claiming that the work of isolating the DNA from the body transforms it and makes it patentable. ”
So, they claim they aren’t actually patenting the two genes, they are patenting transformed version of the genes? To me this would invalidate the work of the human genome project, as they cataloged not the human genome but some variation thereof… Or am I understanding the claim incorrectly?
They’re claiming that isolated DNA is “transformed”, so the not-found-in-nature requirement of a patent doesn’t apply to the genes.